정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 135 | Terminated | Treating COVID-19 With Hydroxychloroquine (TEACH) | COVID-19 | Drug: Hydroxychloroquine (HCQ) Other: Pacebo: Calcium citrate |
Phase 2 | NYU Langone Health, State University of New York - Downstate Medical Center | OTHER | 131 | All | 18 Years | State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States NYU Langone Health, New York, New York, United States |
| 134 | Terminated | Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection | Acute Lung Injury | Drug: VIB7734 Drug: Placebo |
Phase 1 | Viela Bio | INDUSTRY | 10 | All | 18 Years ~ 80 Years | Research Site, Cleveland, Ohio, United States |
| 133 | Recruiting | Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection | Pneumonia Caused by Human Coronavirus (Disorder) | Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) |
Not Applicable | Beijing 302 Hospital | OTHER | 150 | All | 14 Years ~ 80 Years | The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China |
| 132 | Active, not recruiting | Treatment for COVID-19 in High-Risk Adult Outpatients | SARS-CoV-2 | Drug: Ascorbic Acid Drug: Hydroxychloroquine Sulfate Drug: Azithromycin Drug: Folic Acid Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] |
Phase 3 | University of Washington, Bill and Melinda Gates Foundation | OTHER | 300 | All | 18 Years ~ 80 Years | Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States Tulane University, New Orleans, Louisiana, United States Boston University, Boston, Massachusetts, United States SUNY Upstate Medical University, Syracuse, New York, United States University of Washington Coordinating Center, Seattle, Washington, United States UW Virology Research Clinic, Seattle, Washington, United States |
| 131 | Recruiting | Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center | Covid19 | Drug: Colchicine Drug: Prednisone tablet Drug: standard of care |
Phase 3 | Maria Joyera Rodriguez | OTHER | 144 | All | 65 Years | Centre Blauclinic Dolors Aleu, Barcelona, Spain Hospital Clinic, Department of Internal Medicine, Barcelona, Spain Clinica Sant Antoni, Barcelona, Spain |
| 130 | Active, not recruiting | Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease | COVID-19 | Drug: Hydroxychloroquine Drug: Azithromycin |
Phase 3 | LCMC Health | OTHER | 600 | All | 18 Years ~ 100 Years | University Medical Center New Orleans, New Orleans, Louisiana, United States |
| 129 | Not yet recruiting | Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients | Immunoglobulin of Cured Patients | Drug: Immunoglobulin of cured patients Drug: γ-Globulin |
Not Applicable | Wuhan Union Hospital, China | OTHER | 10 | All | 18 Years | Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China |
